Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer

NCT00403130 is registered in ClinicalTrials.gov with George Albert Fisher as lead sponsor.

NCT NCT00403130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00403130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer
Lead sponsor
George Albert Fisher
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
November 30, 2012
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer